CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
<< View More Conferences
2017 SGO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian Cancer
Dr. Altman on Neoadjuvant Chemotherapy in High-Grade Serous Carcinoma
Dr. Brown on Genetic Counseling for Breast and Ovarian Cancer
Oncology Conference Articles
Maintenance Rucaparib Extended PFS in Women with Platinum-Sensitive Recurrent Ovarian Cancer
Rucaparib delayed disease recurrence in the intent to treat population and across subgroups of women with ovarian cancer.
Secondary Cytoreductive Surgery Shows Promise in Ovarian Cancer
Jalid Sehouli, MD, PhD, discusses the significance of these findings in the treatment of patients with platinum-sensitive recurrent ovarian cancer.
Tisotumab Vedotin Shows Clinical Benefit and Ongoing Responses in Cervical Cancer
A first-in-human study showed that the antibody drug conjugate tisotumab vedotin was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer.
No Overall Survival Advantage in Frontline Nintedanib With Chemotherapy in Advanced Ovarian Cancer
The final analysis of overall survival data from the phase III AGO-OVAR 12 trial of nintedanib plus carboplatin/paclitaxel versus carboplatin/paclitaxel alone in women with chemotherapy-naive advanced ovarian cancer did not demonstrate a survival advantage with the addition of nintedanib.
Salvage Surgery Improved PFS in Platinum-Sensitive Recurrent Ovarian Cancer
Patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score experienced prolonged progression-free survival after undergoing a second cytoreductive surgery followed by platinum-based chemotherapy.
Immunotherapy AXAL Tops Survival Mark in Cervical Cancer
An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.
Maintenance Chemotherapy Yields No OS Benefit in Ovarian Cancer
Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.
Maintenance Olaparib Shows Impressive PFS Benefit for BRCA+ Ovarian Cancer
Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed
-mutant ovarian cancer.
Carboplatin Hypersensitivity Linked to BRCA Deficiency in Ovarian Cancer
Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with
-proficient ovarian cancer.
MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer
Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.
Niraparib Effective in Ovarian Cancer, Regardless of BRCA Status
The PARP inhibitor niraparib improved progression-free survival in patients with recurrent, platinum-sensitive, high-grade ovarian cancer, regardless of
status, according to a review of the phase III ENGOT-OV16/NOVA trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.
Parents Continue to See HPV Vaccine as Unnecessary and Worry Over Its Safety
A survey was given to parents of teenage girls in an effort to understand the relatively low uptake of the HPV vaccine in the United States.
Tumor Gene Methylation May Predict Ovarian Cancer Response to Rucaparib
Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib (Rubraca).
Gynecologic Oncologists Cite Time, Money as Barriers to Global Health Participation
Lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities, according to a study reported at the Society of Gynecologic Oncology in National Harbor, MD.
New Insights Into Rucaparib Activity in Ovarian Cancer
The PARP inhibitor rucaparib slowed progression of relapsed
-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Durvalumab Improves Survival in Stage III NSCLC
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Patel Provides Perspective on Immunotherapy Developments in NSCLC
Selinexor Tested in Combination With Standard Therapy in Multiple Myeloma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.